Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
39 studies found for:    MLN9708
Show Display Options
Rank Status Study
1 Recruiting MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Condition: Advanced Cancers
Interventions: Drug: MLN9708;   Drug: Vorinostat
Phase: Phase 1
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: June 2014
Primary Completion: June 2021
2 Recruiting Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: SCRI Development Innovations, LLC;   Millennium Pharmaceuticals, Inc.
Study Start: August 2014
Primary Completion: June 2017
3 Recruiting Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib Citrate in Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Ixazomib Citrate;   Drug: Placebo
Phase: Phase 1
Sponsor: Takeda
Study Start: July 2014
Primary Completion: December 2015
4 Recruiting MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: MLN9708;   Radiation: Questionnaires
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
Study Start: December 2012
Primary Completion: December 2017
5 Active, not recruiting Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
Phase: Phase 1
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: May 2011
Primary Completion: December 2013
6 Recruiting MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
Condition: Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Intervention: Drug: MLN9708
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Mehdi Hamadani;   Medical College of Wisconsin
Study Start: November 2014
Primary Completion: September 2021
7 Not yet recruiting Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia
Interventions: Drug: MLN 9708;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Methotrexate
Phase: Phase 1
Sponsor/Collaborators: Massachusetts General Hospital;   Millennium Pharmaceuticals, Inc.
Study Start: August 2014
Primary Completion: October 2017
8 Recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Nantes University Hospital
Study Start: October 2014
Primary Completion: January 2019
9 Recruiting A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
Conditions: Multiple Myeloma;   Autologous Stem Cell Transplant
Interventions: Drug: Ixazomib Citrate;   Drug: Placebo
Phase: Phase 3
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: July 2014
Primary Completion: February 2018
10 Recruiting Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Ixazomib (MLN9708);   Drug: Dexamethasone
Phase: Phase 2
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: March 2014
Primary Completion: September 2016
11 Recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
Phase: Phase 1
Sponsor: Case Comprehensive Cancer Center
Study Start: May 2014
Primary Completion: July 2015
12 Recruiting Phase I Study of (Modified VXLD) Plus MLN9708 in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia;   Relapsed or Refractory Lymphoma
Interventions: Drug: MLN9708;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: PEG asparaginase;   Drug: Dexamethasone
Phase: Phase 1
Sponsor/Collaborators: Ehab L Atallah;   Medical College of Wisconsin
Study Start: October 2013
Primary Completion: December 2017
13 Not yet recruiting Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Condition: Lymphoma, T-Cell
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor: University of Michigan Cancer Center
Study Start: August 2014
Primary Completion: August 2018
14 Recruiting Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Conditions: Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
Intervention: Drug: MLN9708
Phase: Phase 2
Sponsor/Collaborators: Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
Study Start: July 2014
Primary Completion: July 2016
15 Withdrawn MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone
Phase: Phase 2
Sponsor/Collaborators: National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
Study Start: July 2012
Primary Completion: March 2014
16 Recruiting A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Drug: ixazomib + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
Phase: Phase 3
Sponsor: Millennium Pharmaceuticals, Inc.
Study Start: August 2012
Primary Completion: December 2014
17 Not yet recruiting Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
Condition: Leukemia
Intervention: Drug: Ixazomib
Phase: Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Millennium: The Takeda Oncology Company
Study Start: April 2015
Primary Completion: April 2021
18 Suspended Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Treating Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions: Drug: ixazomib;   Drug: mitoxantrone hydrochloride;   Drug: etoposide;   Drug: cytarabine
Phase: Phase 1
Sponsor/Collaborators: Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Study Start: October 2014
Primary Completion: November 2017
19 Recruiting Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Condition: Refractory Multiple Myeloma
Interventions: Drug: ixazomib;   Drug: dexamethasone
Phase: Phase 2
Sponsor/Collaborators: Mayo Clinic;   National Cancer Institute (NCI)
Study Start: January 2012
Primary Completion: December 2014
20 Recruiting Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: ixazomib;   Drug: dexamethasone;   Drug: pomalidomide;   Other: laboratory biomarker analysis
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: City of Hope Medical Center;   National Cancer Institute (NCI)
Study Start: June 2014
Primary Completion: June 2017

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Indicates status has not been verified in more than two years